Aclaris Therapeutics, Inc. Acquisitions, Net of Cash Acquired
Aclaris Therapeutics, Inc. (ACRS) reported Acquisitions, Net of Cash Acquired of $9.65 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2020-02-25
- Aclaris Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2017-12-31 was $0.00.
- Aclaris Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2017 was $9.65M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $9.65M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $9.65M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |